ARVO 2020: Satralizumab Reduces Relapse Risk in Neuromyelitis Optica Spectrum Disorder in Pooled Analysis
Benefits were seen in particularly in patients who were seropositive for the aquaporin 4 IgG antibody
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.